Kusaka Gen, Ishikawa Mami, Nanda Anil, Granger D Neil, Zhang John H
Department of Neurosurgery, Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana 71130-3932, USA.
J Cereb Blood Flow Metab. 2004 Aug;24(8):916-25. doi: 10.1097/01.WCB.0000125886.48838.7E.
Few studies have examined the signaling pathways that contribute to early brain injury after subarachnoid hemorrhage (SAH). Using a rat SAH model, the authors explored the role of vascular endothelial growth factor (VEGF) and mitogen-activation protein kinase (MAPK) in early brain injury. Male Sprague-Dawley rats (n = 172) weighing 300 to 350 g were used for the experimental SAH model, which was induced by puncturing the bifurcation of the left anterior cerebral and middle cerebral arteries. The blood-brain barrier (BBB), brain edema, intracranial pressure, and mortality were evaluated at 24 hours after SAH. The phosphorylation of VEGF and different MAPK subgroups (ERK1/2, p38, and JNK) were examined in both the cortex and the major cerebral arteries. Experimental SAH increased intracranial pressure, BBB permeability, and brain edema and produced high mortality. SAH induced phosphorylation of VEGF and MAPKs in the cerebral arteries and, to a lesser degree, in the cortex. PP1, an Src-family kinase inhibitor, reduced BBB permeability, brain edema, and mortality and decreased the phosphorylation of VEGF and MAPKs. The authors conclude that VEGF contributes to early brain injury after SAH by enhancing the activation of the MAPK pathways, and that the inhibition of these pathways might offer new treatment strategies for SAH.
很少有研究探讨蛛网膜下腔出血(SAH)后导致早期脑损伤的信号通路。作者利用大鼠SAH模型,探究血管内皮生长因子(VEGF)和丝裂原活化蛋白激酶(MAPK)在早期脑损伤中的作用。体重300至350克的雄性Sprague-Dawley大鼠(n = 172)用于实验性SAH模型,该模型通过穿刺左大脑前动脉和大脑中动脉的分叉处诱导产生。在SAH后24小时评估血脑屏障(BBB)、脑水肿、颅内压和死亡率。检测了皮质和大脑主要动脉中VEGF和不同MAPK亚组(ERK1/2、p38和JNK)的磷酸化情况。实验性SAH增加了颅内压、BBB通透性和脑水肿,并导致高死亡率。SAH诱导大脑动脉中VEGF和MAPKs的磷酸化,在皮质中诱导程度较小。Src家族激酶抑制剂PP1降低了BBB通透性、脑水肿和死亡率,并降低了VEGF和MAPKs的磷酸化。作者得出结论,VEGF通过增强MAPK通路的激活促成SAH后的早期脑损伤,抑制这些通路可能为SAH提供新的治疗策略。